| 0.005 0.002 (45.45%) 08-08 09:59 |
|
| Open: | 0.005 |
| High: | 0.008 |
| Low: | 0.004 |
| Pre. close: | 0.003 |
| Volume: | 332,342,448 |
| Avg. volume: | 63,877,536 |
| MA (50): | 0.004 |
| MA (200): | 0.063 |
| Year high: | 1.040 |
| Year low: | 0.001 |
| Market cap: | 1(M) |
| EPS: | -1.2 |
| PE ratio: | 0 |
| SELL | BUY |
| HeikinAshi: | |
| Kaufmans AMA: | |
| Chandelier (20): | |
| MA (5): | |
| MA (50): | |
| MACD (26,12,9): | |
| Slow KDJ (14,3): | |
| RSI (14): | |
| CCI (20): |
Tue, 02 Aug 2022
Charcot-Marie-Tooth Disease Type I A Drug Market Trend | Demand and Import/Export Details up to 2030 – Addex Therapeutics Ltd, Affectis Pharmaceuticals AG, Genzyme Corp – Shanghaiist - Shanghaiist
Sun, 15 May 2022
New Data from the Open-Label PLEO-CMT-FU Trial Shows Sustained Benefit with PXT3003 in Patients with Charcot-Marie-Tooth Disease Type 1A After 5 Years of Total Trial Time - Yahoo Finance
Thu, 10 Mar 2022
Charcot-Marie-Tooth Disease Market is expected to increase to US$ 3,459.1 Million by 2028, witnessing a CAGR of 23.4% Major Players are Addex Therapeutics Ltd., Affectis Pharmaceuticals AG - Medgadget
Mon, 27 Dec 2021
Charcot-Marie-Tooth Disease Market Size Is Anticipated To Reach USD 3459.1 Million at a CAGR of 23.4% By 2028 | Addex Therapeutics Ltd., Affectis Pharmaceuticals AG, Genzyme Corp, Lead Discovery Center GmbH - Medgadget
Wed, 20 Oct 2021
Charcot-Marie-Tooth Disease Market to Surpass US$ 3,459.1 - GlobeNewswire
Wed, 28 Apr 2021
Interim Analysis from the Ongoing Open-Label Phase III Extension Study Shows Sustained Benefits of PXT3003 for Patients with Charcot-Marie-Tooth Disease Type 1A ('CMT1A') - GlobeNewswire
|
©NovaStocks.com | euro Stocks quote, company news, stock charts, technical analysis. Data and information is provided for informational purposes only, is not intended for trading purposes and is not investment advice. Neither NovaStocks.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Market data provided by: Financial Modeling Prep
Privacy Policy: Third parties, including Google, may be placing and reading cookies on your browsers, or other methods to collect information as a result of ad serving on this website. Third parties' use of advertising cookies enables it and its partners to serve ads to you based on your visit to this site and/or other sites on the Internet. You may opt out of personalized advertising by visiting Ads Settings. If you choose to use this website, you agree to the collection and use of information in relation to this policy. The information collected is used for providing and improving the ads Service. We will not use or share information with anyone, and we do not store any data from users.
